NOTE 8 – INTANGIBLE ASSETS

The Company’s intangible assets consisted of the following at March 31, 2026 and December 31, 2025:

Patents

On October 12, 2018 the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals Inc. acquired six patent families for sustained delivery platforms for the local delivery of biologic and small molecule drugs for an aggregate purchase price of $15,200. Amortization is computed on straight-line method based on estimated useful lives of 13 years. During the three months ended March 31, 2026 and 2025, the Company recorded amortization expense of $295 and $294, respectively. During the three months ended March 31, 2026, the Company recorded an impairment of intellectual property of $6,374 and derecognized the patents.

Trademark

The fair value of trademark acquired in the business combination on March 4, 2025 was $249,500. Trademark is not amortized, but is tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment was recognized for the three months ended March 31, 2026 and 2025.

Customer base

The fair value of customer base acquired in the business combination on March 4, 2025 was $336,200. Amortization is computed on straight-line method based on estimated useful lives of 10 years. During the three months ended March 31, 2026 and 2025, the Company recorded amortization expense of $8,290 and $20,785, respectively. As of March 31, 2026, the accumulated amortization was $36,199.

The future amortization of the customer base are as follows: